You are here: Industry Insights > RedHill

News List

RedHill sees positive results for anti-MAP Crohn's drug pharmatimes
July 31, 2018
RedHill Biopharma has announced positive results from the first Phase III study of its Crohn's disease drug RHB-104 - making it the first global, double-blind, placebo-controlled study to demonstrates the efficacy of anti-MAP therapy in this hard-to-treat
RedHill Biopharma announces successful Phase III pharmaasia
July 04, 2017
RedHill Biopharma announces successful Phase III top-line results with BEKINDA for Acute Gastroenteritis.
RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D b3cnewswire
April 26, 2017
RedHill Biopharma Ltd. announced enrollment of the last patient in the Phase II study with BEKINDA® (RHB-102)(1) 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product Ente b3cnewswire
April 06, 2017
RedHill Biopharma Ltd. announced the signing of an exclusive license agreement with Entera Health Inc. (“Entera Health”).
RedHill Biopharma announces dosing of first patient in the phase III study with RHB-104 biospectrumasia
March 23, 2017
The open-label extension study is intended to assess the safety and efficacy of RHB-104 in patients who have completed 26 weeks of treatment in the ongoing Phase III study
RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III S b3cnewswire
March 22, 2017
A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countries.
RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous b3cnewswire
January 13, 2017
RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection
RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma b3cnewswire
January 09, 2017
The abstract, to be presented at the upcoming 2017 Cholangiocarcinoma Foundation Annual Conference, describes positive findings from non-clinical studies...

Previous page 1 2 3 4 Next page